The results of the analysis of materials on the safety of clinical trials

The results of the analysis of materials on the safety of clinical trials

The article presents the results of the Scientific Centre for Expert Evaluation of Medicinal Products», Ministry of Health of Russia of the analysis and generalization of materials on the safety of clinical trials of medicines for medical use (including international multi-center clinical trials), p...

Full description

Bibliographic Details
Main Author:	Yu. V. Olefir
Format:	Article
Language:	Russian
Published:	Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation 2018-02-01
Series:	Безопасность и риск фармакотерапии
Subjects:	анализ обобщение безопасность клиническое исследование лекарственное средство разрабатываемый препарат серьезное нежелательное явление серьезная нежелательная реакция отчет по безопасности разрабатываемого лекарственного препарата analysis synthesis drug safety clinical trials medicines serious adverse event serious adverse reaction
Online Access:	https://www.risksafety.ru/jour/article/view/62

Similar Items

Assessment of Pharmacovigilance Reporting in Russia
by: Yu. V. Olefir, et al.
Published: (2018-12-01)

Standard form of a periodic safety update report
by: B. R. Romanov, et al.
Published: (2018-02-01)

Специалист по фармакологической безопасности в фармацевтической компании
Published: (2018-06-01)

COMPARATIVE EVALUATION OF INFORMATION ON ADVERSE REACTIONS TO MEDICINES
by: V. K. Lepakhin, et al.
Published: (2018-02-01)

Clinical trials in pregnancy: evaluation of benefit/risk?
by: E. A. Sokova, et al.
Published: (2018-02-01)

Guidelines for the planning and implementation of pharmacovigilance systems audit
by: S. V. Glagolev, et al.
Published: (2018-02-01)

Выбор препарата для лекарственной терапии с учетом особенностей субстанции
by: С. С. Вялов, et al.
Published: (2012-08-01)

Экономические преимущества и слабые стороны генериков в системе лекарственного обеспечения населения в России и за рубежом
Published: (2018-06-01)

Perfection of management principles by the safety signals of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

SUGGESTIONS FOR PREVENTING UNDESIRED REACTIONS AT APPLICATION IMMUNOBIOLOGICAL MEDICINAL PRODUCTS IN THE RUSSIAN FEDERATION
by: N. A. Ozeretskovsky, et al.
Published: (2018-02-01)

A photosensitivity reaction to phenobarbital after taking ibuprofen
by: S. S. Postnikov, et al.
Published: (2018-02-01)

Guidelines for the Preparation of a Document Containing the Drug Safety Monitoring Results
by: Yu. V. Olefir, et al.
Published: (2018-02-01)

Modern approaches to collecting and reporting information on side effects
by: K. E. Zatolochina, et al.
Published: (2018-02-01)

Results of an opinion poll devoted to unification of instructions for interchangeable medicines
by: N. G. Goloenko, et al.
Published: (2018-02-01)

Difficulties in Differential Diagnosis of Post-Vaccination Period. Practical Examples
by: E. P. Nacharova, et al.
Published: (2017-12-01)

The revision of the restrictive lists of medicinal products
by: B. K. Romanov, et al.
Published: (2018-02-01)

Monitoring post-approval drug safety in pregnancy: pharmacogenetic aspects
Published: (2018-02-01)

«Propofol infusion syndrome» - case in a child of 10 years
by: S. S. Postnikov, et al.
Published: (2018-02-01)

Эффективность и безопасность толперизона гидрохлорида в лечении синдрома болезненного рефлекторного мышечного спазма
Published: (2018-06-01)

Social media as a source of information on drug safety and how to extract it
by: I. I. Snegireva, et al.
Published: (2018-02-01)

Identification and assessment of cases of malignant hyperthermia triggering under anaesthetic management: analysis of spontaneous reporting database
by: E. Yu. Kolesnikova, et al.
Published: (2018-02-01)

Recommendations for evaluating the safety of medicinal products containing nanoparticles
by: R. N. Alyautdin, et al.
Published: (2018-02-01)

Practical recommendations for screening of information on the drug safety
by: E. Yu. Pasternak, et al.
Published: (2018-02-01)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
by: Elizabeth C. James, et al.
Published: (2020-09-01)

QSAR-анализ природных соединений
by: Хамза Сайидмуродович Тошов, et al.
Published: (2021-04-01)

Rare serious adverse effects of clozapine (tur)
by: Özcan Uzun
Published: (2020-11-01)

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
by: Cédric B. Chesnais, et al.
Published: (2020-11-01)

The risk management system as the important part of good pharmacovigilance practices (GVP)
by: A. S. Kazakov, et al.
Published: (2018-02-01)

Клиническое исследование мидокалма (толперизона гидрохлорида)
Published: (2018-06-01)

Рандомизированное контролируемое клинико-экономическое исследование применения Прогепара у пациентов с хроническим алкогольным гепатитом
Published: (2018-06-01)

Personalized approach to optimization of the pharmaceutical care in the hospital segment
by: L N Heller, et al.
Published: (2013-12-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Ethics of safety reporting of a clinical trial
by: Amrita Sil, et al.
Published: (2017-01-01)

Typical pharmacovigilance system master file (PSMF)
by: B. K. Romanov, et al.
Published: (2018-02-01)

What should we report? Lessons learnt from the development and implementation of serious adverse event reporting procedures in non-pharmacological trials in palliative care
by: Lesley Dunleavy, et al.
Published: (2021-01-01)

Pharmacovigilance for clinical trials in India: Current practice and areas for reform
by: Ballari Brahmachari, et al.
Published: (2011-01-01)

Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting
by: Gwenllian Moody, et al.
Published: (2019-12-01)

Pitfalls of patenting and state authorization of medicines
by: V. I. Semenov, et al.
Published: (2018-02-01)

An analysis of serious adverse drug reactions at a tertiary care teaching hospital
by: Kinjal Prajapati, et al.
Published: (2016-01-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)